HemaQuest Pharmaceuticals, Inc.: Series B $13M

Posted in I - Series B, Q - 1Q11, R - WEST, X - Beta Thalassemia, X - Hemoglobin, X - Sickle Cell, XX - CA

HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]

Apr

2010

HemaQuest Pharmaceuticals, Inc. Series B $12M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - Hemoglobin, X - HIV, X - HPV, X - Sickle Cell, XX - MA

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Dec

2009

GlycoMimetics, Inc.: Series C $38M

Posted in I - Series C, Q - 4Q09, R - MID ATLANTIC, X - GlycoBiology, X - Inflammation, X - Oncology, X - Sickle Cell, XX - MD

GlycoMimetics (Gaithersburg, MD) a clinical-stage small molecule glycobiology company focused on cancer, inflammation and infectious disease, closed a $38M Series C financing. Participants include Genzyme Ventures, New Enterprise Associates, Novartis Venture Fund, Anthem Capital Management and Alliance Technology Ventures. A more detailed company profile recently appeared on Life Science Deal Flow [HERE].

to top of page...